The Liver Center, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA.
Clin Gastroenterol Hepatol. 2012 Aug;10(8):932-937.e1. doi: 10.1016/j.cgh.2012.01.015. Epub 2012 Jan 28.
BACKGROUND & AIMS: Hepatic elastography (HE) is a noninvasive technique that measures liver stiffness and is used to diagnose hepatic fibrosis. It can help patients who are thought to have early-stage disease avoid a staging liver biopsy, but only when confounding variables that increase liver stiffness are excluded. Chronic inflammation from hepatitis C virus (HCV) infection is not considered to be one of these variables.
We identified 684 patients with HCV and METAVIR fibrosis scores of 0-2 from a prospective, multi-institutional study of liver stiffness in 2880 patients with chronic liver disease. Patients were 49.6 ± 9.0 years old, 64.3% were male, and they had an average body mass index of 26.7 ± 4.1 kg/m(2).
In a multivariate analysis, inflammation (based on histologic analysis) and level of alanine aminotransferase (ALT) were associated with liver stiffness. The chances of a patient having a level of stiffness that indicates cirrhosis increased with grade of inflammation and level of ALT. By using a conservative 14.5-kPa cutoff for the diagnosis of cirrhosis, grade 3 inflammation had an odds ratio of 9.10 (95% confidence interval, 2.49-33.4). Likewise, levels of ALT greater than 80 and 120 IU/L had odds ratios of 3.84 (95% confidence interval, 2.10-7.00) and 4.10 (95% confidence interval, 2.18-7.69), respectively. The effect of the level of ALT persisted when analysis was restricted to patients with fibrosis scores of F0 to F1.
In patients with HCV infection and early-stage fibrosis, increased levels of ALT correlate with liver stiffness among patients in the lowest strata of fibrosis (METAVIR scores 0-2). Patients without fibrosis but high levels of ALT could have liver stiffness within the range for cirrhosis. Inflammation should be considered a confounding variable in analysis of liver stiffness.
肝脏弹性成像(HE)是一种测量肝硬度的非侵入性技术,用于诊断肝纤维化。它可以帮助那些被认为患有早期疾病的患者避免进行分期肝活检,但前提是排除增加肝硬度的混杂因素。丙型肝炎病毒(HCV)感染引起的慢性炎症不被认为是这些因素之一。
我们从一项针对 2880 例慢性肝病患者的肝硬度的前瞻性多机构研究中,确定了 684 例 HCV 且 METAVIR 纤维化评分 0-2 的患者。患者年龄为 49.6±9.0 岁,64.3%为男性,平均体重指数为 26.7±4.1kg/m²。
在多变量分析中,炎症(基于组织学分析)和丙氨酸氨基转移酶(ALT)水平与肝硬度相关。炎症程度和 ALT 水平越高,患者出现提示肝硬化的肝硬度水平的可能性就越大。使用保守的 14.5kPa 临界值诊断肝硬化时,3 级炎症的比值比为 9.10(95%置信区间,2.49-33.4)。同样,ALT 水平大于 80 和 120IU/L 的比值比分别为 3.84(95%置信区间,2.10-7.00)和 4.10(95%置信区间,2.18-7.69)。当分析仅限于纤维化评分 F0 至 F1 的患者时,ALT 水平的影响仍然存在。
在 HCV 感染和早期纤维化的患者中,ALT 水平升高与纤维化程度最低(METAVIR 评分 0-2)的患者的肝硬度相关。没有纤维化但 ALT 水平较高的患者可能具有肝硬化范围内的肝硬度。炎症应被视为分析肝硬度时的混杂因素。